The two major tranquillizers, methylperidol and trifluoperazine, are compared as treatments for underactive, chronic schizophrenic patients. They are found to be equally effective.
References
1.
CawleyR. H. (1967). The present status of physical methods of treatment of schizophrenia, in CoppenA.WalkA. (Eds.). Recent Developments in Schizophrenia: A Symposium. British Journal of Psychiatry Special Publication No. 1. Headley Brothers, Ashford.
2.
HacksteinF. G. (1963). Clinical trials with Luvatrene (methylperidol), a butyrophenone derivative. Therapiewoche, 11: 485.
3.
HarrisA. D.LetemendiaF. J. J.WillemsP. J. A. (1967). A rating scale of the mental state: for use in the chronic population of the psychiatric hospital. Brit. J. Psychiat., 113: 941.
4.
JanssenP. A. J. (1967). The pharmacology of haloperidol. Int. J. Neuropsychiat., Vol. 3, Supplement 1, p. 510.
5.
JonesI. H. (1967). Riboflavin as an indicator of drug taking behaviour. Med. J. Aust., 1: 202.
6.
KraepelinE. (1910). Psychiatrie, 8th Edition, trans. BarclayR.M., ed. Robertson, G. M. (1919). Livingstone, Edinburgh.
7.
PlatzA. R.KlettC. J.CaffeyE.M.Jr (1966). Selective drug action related to chronic schizophrenic subtype. A comparative study of perphenazine, chlorpromazine and trifluoperazine. Co-operative Studies in Psychiatry, Report No. 68. Perry Point, Maryland. Quoted in Psycho-pharmacology Abstracts, 6: 382.
8.
RogersN. R. (1963). Trifluoperazine as a “mobilising agent” in chronic, withdrawn schizophrenics. Dis. nerv. Syst., 24: 162.
9.
VenablesP. H. (1957). A short scale for rating “activity-withdrawal” in schizophrenics. J. ment. Sci., 103: 197.
10.
WittenbornJ. R. (1955). Manual: Wittenborn Psychiatric Rating Scales. The Psychological Corporation, New York.
